文献速递骨质疏松与代谢性骨病创伤骨科

癌症患者发生骨折后很少接受骨质疏松评估或治疗:一项基于人群的研究

Cancer patients with fractures are rarely assessed or treated for osteoporosis: a population-based study.
PubMed 文献 · Osteoporos Int · 2020-08-17

该研究基于加拿大马尼托巴省人群数据库,纳入4238例癌症患者和16418例无癌症对照,均发生重大非创伤性骨折。骨折后12个月内,两组在骨密度检测(11.0% vs 11.5%)、骨质疏松治疗(22.9% vs 21.8%)及任一干预(28.9% vs 28.4%)方面均无显著差异,总体照护缺口巨大。作者认为可能需要为癌症人群制定照护路径以改善骨折后照护。

要点

  • 癌症患者骨折后12个月内骨密度检测率仅11.0%,与无癌症对照的11.5%相当(P=0.43)。
  • 癌症患者骨质疏松治疗启动率22.9%,无癌症对照为21.8%(P=0.15),差异无统计学显著。
  • 骨折后接受任一干预(骨密度检测和/或骨质疏松治疗)的比例在癌症组为28.9%,对照组为28.4%(P=0.53)。

核心结论

  • 癌症患者发生骨折后存在很大的照护缺口,与普通人群相似,骨质疏松的评估或治疗很少开展。
  • 作者认为可能需要为癌症人群制定照护路径以改善骨折后照护。

研究设计与样本

  • 基于人群的数据库研究,利用马尼托巴省癌症登记处识别1987年至2013年间首次诊断为癌症的病例,并从省级医生账单理赔和住院数据库识别无癌症对照。
  • 纳入发生重大非创伤性骨折(髋部、临床椎体、前臂、肱骨)且骨折后随访至少1年的4238例癌症患者和16418例无癌症对照。
  • 结局为骨折后12个月内进行骨密度检测(来自骨密度登记处)、启动骨质疏松治疗(来自药物分发数据库)或任一干预(骨密度检测和/或骨质疏松治疗)。

主要发现

  • 癌症组骨折后骨密度检测率为11.0%,无癌症对照组为11.5%(P=0.43)。
  • 癌症组骨质疏松治疗启动率为22.9%,无癌症对照组为21.8%(P=0.15)。
  • 癌症组接受任一干预(骨密度检测和/或骨质疏松治疗)的比例为28.9%,无癌症对照组为28.4%(P=0.53)。
  • 骨密度检测和/或启动治疗的预测因素在癌症与非癌症患者中相似。
  • 骨折后干预在女性、年龄50岁及以上者、较晚日历期发生骨折者中更常使用,且在椎体骨折后治疗更常使用;癌症特异性变量(癌症类型、从癌症诊断到骨折的年数、照护提供者专科)仅显示微弱且不一致的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Among 4238 cancer and 16,418 cancer-free individuals with incident major non-traumatic fractures (hip, clinical vertebral, forearm, humerus), post-fracture osteoporosis care was equally poor for both groups, whether assessed from bone mineral density (BMD) testing, initiation of osteoporosis therapy or either intervention (BMD testing and/or osteoporosis therapy). INTRODUCTION: Most individuals sustaining a fracture do not undergo evaluation and/or treatment for osteoporosis. Cancer survivors are at increased risk for osteoporosis and fracture. Whether cancer survivors experience a similar post-fracture "care gap" is unclear. Using population-based databases, we assessed whether cancer patients are evaluated and/or treated for osteoporosis after a major fracture. METHODS: From the Manitoba Cancer Registry, we identified cancer cases (first cancer diagnosis between 1987 and 2013) and cancer-free controls with incident major non-traumatic fractures (from provincial physician billing claims and hospitalization databases). The outcomes were performance of BMD testing (from the BMD Registry), initiation of osteoporosis therapy (from drug dispensation database) or either intervention (BMD testing and/or osteoporosis therapy) in the 12 months post-fracture. RESULTS: There were 4238 cancer and 16,418 cancer-free individuals who sustained a fracture after the index date (cancer diagnosis) and were followed for at least 1 year post-fracture. Subsequent BMD testing was performed in 11.0% of cancer cases versus 11.5% non-cancer controls (P = 0.43), osteoporosis treatment in 22.9% cancer cases versus 21.8% non-cancer controls (P = 0.15), and either testing or treatment in 28.9% cancer cases versus 28.4% non-cancer controls (P = 0.53). Predictors of BMD testing and/or initiation of therapy were similar for non-cancer and cancer patients. Post-fracture interventions were consistently used more frequently among women, older patients (age 50 years or older), those who sustained fractures in a later calendar period, and (for treatment) after vertebral fracture. Cancer-specific variables (cancer type, years from cancer diagnosis to fracture, specialty of care provider) showed only weak and inconsistent effects. CONCLUSIONS: A large care gap exists among cancer patients who sustain a fracture, similar to the general population, whereby the evaluation or treatment for osteoporosis is seldom conducted. Care maps may need to be developed for cancer populations to improve post-fracture care.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Leslie WD, Edwards B, Al-Azazi S, et al. Cancer patients with fractures are rarely assessed or treated for osteoporosis: a population-based study. Osteoporos Int. 2020. PMID: 32808139. doi:10.1007/s00198-020-05596-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。